PositoAI/ US/ Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

NasdaqGS: ZBIO · Healthcare

Positivity Index

#5,598 / 6,774

Global

#3,072 / 4,000

United States

Positivity Score

16,694

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Zenas BioPharma, Inc. — Overview & Financial Snapshot

Zenas BioPharma, Inc. (NasdaqGS: ZBIO) is a Healthcare company, ranked #5,598 of 6,774 companies globally and #3,072 of 4,000 in United States on PositoAI, with a Positivity Score of 16,694. Its market capitalisation is ₹17,367.33 Cr ($1.84B), P/E ratio is -2.9 and P/B ratio is 7.45. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

P/B Ratio 7.45

P/E Ratio -2.9

D/E Ratio 1.21

ROE -199.04%

Owes vs Owns ? 0.65× Moderate $0.65 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-908.98$-9.63

Forward EPS ₹-439.86$-4.66

Beta -0.88

Market Cap ₹17,367.33 Cr$1.84B

What these numbers mean →

What does Zenas BioPharma, Inc. do?

What is Zenas BioPharma, Inc.'s P/E and P/B ratio?

Zenas BioPharma, Inc. has a P/E ratio of -2.9 and a P/B ratio of 7.45.

What is Zenas BioPharma, Inc.'s debt-to-equity ratio?

Zenas BioPharma, Inc. has a debt-to-equity ratio of 1.21.

How much does Zenas BioPharma, Inc. owe compared with what it owns?

Zenas BioPharma, Inc. owes $0.65 for every $1 it owns (balance sheet Jun 2026), which is moderate.

What is Zenas BioPharma, Inc.'s Positivity rank?

Zenas BioPharma, Inc. is ranked #5,598 of 6,774 companies globally and #3,072 of 4,000 in United States on PositoAI, with a Positivity Score of 16,694.

Does Zenas BioPharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Zenas BioPharma, Inc..

Where can I read the latest news about Zenas BioPharma, Inc.?

Recent headlines about Zenas BioPharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Zenas BioPharma, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Zenas BioPharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.